CLINICAL_TRIALS trial_result · 2017-02-28

Clinical Trial Update: Phase 2 Study of Bexxar in Relapsed/Refractory DLCL [Phase 2]

Phase 2 trial of Bexxar (tositumomab) in relapsed or refractory diffuse large B-cell lymphoma has completed. Results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Susan Knox | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-28